Danaparoid: an antithrombotic agent without major impact on triglyceride hydrolysis capacity in humans.

INIS

• humans 100%
• capacity 100%
• triglycerides 100%
• heparin 100%
• hydrolysis 100%
• lipase 83%
• drugs 66%
• lipoproteins 66%
• patients 50%
• comparative evaluations 33%
• in vitro 33%
• universities 33%
• sulfates 33%
• anticoagulants 33%
• doses 16%
• therapy 16%
• risks 16%
• netherlands 16%
• hospitals 16%
• design 16%
• metabolism 16%
• in vivo 16%
• dialysis 16%
• accumulation 16%
• lipids 16%
• intravenous injection 16%
• internal medicine 16%

Keyphrases

• Heparin 100%
• Antithrombotic Agents 100%
• Danaparoid 100%
• Triglyceride Hydrolysis 100%
• Hydrolysis Capacity 100%
• Lipase 50%
• Lipolysis 50%
• Antithrombotic Drugs 50%
• Hemodialysis Patients 33%
• Triglyceride-rich Lipoproteins 33%
• Lipoprotein Lipase 33%
• Heparan Sulfate 33%
• Netherlands 16%
• Lipid Metabolism 16%
• Intravenous Injection 16%
• Anticoagulants 16%
• Antithrombotic Therapy 16%
• Drug Choice 16%
• University Hospital 16%
• Internal Medicine 16%
• Utrecht 16%
• Anticoagulant Property 16%
• Dialysis Session 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Anticoagulant Agent 100%
• Heparin 100%
• Triacylglycerol 100%
• Danaparoid 100%
• Pancreatic Lipase 50%
• Lipoprotein 33%
• Hemodialysis 33%
• Heparan Sulfate 33%
• Lipoprotein Lipase 33%
• Antithrombotic Therapy 16%